Concourse Financial Group Securities, Inc. Werewolf Therapeutics, Inc. Transaction History

Concourse Financial Group Securities, Inc.

$0
Q2 2025

Number of Shares

Previous 0 NaN%

Holding current value

Previous $0 NaN%

% of portfolio

100.0%

Previous 100.0%

18 transactions

Quarter	Operation	Price Per share
Q2 2025 Aug 12, 2025	BUY	$0.63 - $1.42 $0 - $0
Q1 2025 May 14, 2025	BUY	$0.97 - $1.68 $0 - $0
Q4 2024 Feb 13, 2025	BUY	$1.48 - $3.63 $0 - $0
Q3 2024 Oct 10, 2024	BUY	$1.71 - $2.95 $0 - $0
Q2 2024 Jul 23, 2024	BUY	$2.34 - $6.75 $0 - $0
Q1 2024 Apr 30, 2024	BUY	$3.92 - $7.91 $0 - $0
Q4 2023 Feb 07, 2024	BUY	$1.78 - $4.15 $0 - $0
Q3 2023 Oct 30, 2023	BUY	$2.0 - $3.82 $0 - $0
Q3 2023 Oct 25, 2023	BUY	$2.0 - $3.82 $0 - $0
Q2 2023 Aug 10, 2023	BUY	$2.31 - $3.65 $0 - $0
Q1 2023 May 15, 2023	BUY	$1.98 - $4.3 $0 - $0
Q4 2022 Jan 30, 2023	BUY	$1.53 - $4.73 $0 - $0
Q3 2022 Nov 15, 2022	BUY	$4.14 - $7.42 $0 - $0
Q2 2022 Aug 09, 2022	BUY	$3.43 - $5.98 $0 - $0
Q1 2022 May 09, 2022	BUY	$3.71 - $12.22 $0 - $0
Q4 2021 Feb 07, 2022	BUY	$11.48 - $17.65 $0 - $0
Q3 2021 Nov 09, 2021	BUY	$13.89 - $20.31 $0 - $0
Q2 2021 Aug 13, 2021	BUY	$11.6 - $17.44 $0 - $0

Others Institutions Holding HOWL

# of Institutions

Shares Held

23.6M

Call Options Held

Put Options Held

Ra Capital Management, L.P. Boston, MA

6.68M
Shares

$7.55 Million
0.16% of portfolio
Mpm Asset Management LLC Cambridge, MA

4.31M
Shares

$4.87 Million
10.84% of portfolio
Bio Impact Capital LLC Cambridge, MA

2.41M
Shares

$2.72 Million
0.51% of portfolio
Bank Of America Corp Charlotte, NC

2.13M
Shares

$2.41 Million
0.0% of portfolio
Black Rock Inc. New York, NY

1.59M
Shares

$1.79 Million
0.0% of portfolio

View Full List

About Werewolf Therapeutics, Inc.

Ticker HOWL
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 29,529,400
Market Cap $33.4M
Description
Werewolf Therapeutics, Inc., a biopharmaceutical company, develops therapeutics engineered to stimulate the body's immune system for the treatment of cancer. The company, through its proprietary PREDATOR platform, designs conditionally activated molecules that stimulate adaptive and innate immunity for addressing the limitations of conventional ...

More about HOWL

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Concourse Financial Group Securities, Inc., based on Form 13F filings with the SEC.

News

Stay updated on Concourse Financial Group Securities, Inc. with notifications on news.

Account